Loading
AVZO-021 is an experimental small-molecule drug from Avenzo Therapeutics in phase 2 trials for HR-positive / HER2-negative breast cancer, ovarian cancer and endometrial cancer, aimed at HER2.
AVZO-021 is a small-molecule drug developed by Avenzo Therapeutics. Its target is HER2 (the sponsor names CDK2). The sponsor states: AVZO-021 is a highly potent and selective oral CDK2 inhibitor targeting the cyclin E-CDK2 pathway, which becomes hyperactivated as a resistance mechanism to CDK4/6 inhibitors in HR+/HER2- breast cancer and other CCNE1-amplified solid tumours. ClinicalTrials.gov describes the intervention as: AVZO-021 is an oral selective CDK2 inhibitor. It is the investigational product in 2 recruiting or active industry-led phase 2 and phase 3 interventional cancer trials, in HR-positive / HER2-negative breast cancer, ovarian cancer, endometrial cancer and triple-negative breast cancer. The largest, NCT05867251, plans to enrol 430 participants with primary completion expected 2028-01-31. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.
AVZO-021 is a highly potent and selective oral CDK2 inhibitor targeting the cyclin E-CDK2 pathway, which becomes hyperactivated as a resistance mechanism to CDK4/6 inhibitors in HR+/HER2- breast cancer and other CCNE1-amplified solid tumours. Connects to HER2.
1.AVZO-021 slips into a pocket on HER2.
Background: ADC sequencing, Antigen escape (antigen loss, lineage switch), BCG-unresponsive, Castration-resistant prostate cancer (CRPC), Circulating tumour DNA (ctDNA). Also on OnCo: Resistance: how tumours escape each drug class · Lines of therapy.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"AVZO-021" OR ABSTRACT:"AVZO-021") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about AVZO-021, not a curated reading list.
Shares Endometrial cancer, Ovarian cancer, HR-positive / HER2-negative breast cancer and the tag pipeline.
Shares Endometrial cancer, Ovarian cancer, Triple-negative breast cancer (TNBC) and the tag pipeline.
Shares Ovarian cancer, Triple-negative breast cancer (TNBC), HR-positive / HER2-negative breast cancer and the tag pipeline.
Shares Endometrial cancer, Ovarian cancer, Triple-negative breast cancer (TNBC) and the tag pipeline.
Shares Avenzo Therapeutics and the tag pipeline.
Shares Avenzo Therapeutics and the tag pipeline.
Shares Endometrial cancer, Ovarian cancer and the tag pipeline.
Shares Endometrial cancer, Ovarian cancer and the tag pipeline.